Reduced incidence and severity of acute radiation mucositis by WF10 (IMMUNOKINE□) as adjunct to standard of cure in the management of head & neck cancer patients

Journal of the Medical Association of Thailand

Volumn 90, Issue 8, 2007, Pages 1590-1600

  Penpattanagul, Somkit ^a  

^a Udonthani Cancer Center   (Thailand)

Author keywords

Chemotherapy; Head and neck cancer; Mucositis; Radiotherapy; Tetrachlorodecaoxygen (TCDO iv, WF10)

Indexed keywords

TETRACHLORODECAOXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSPHAGIA; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; INCIDENCE; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; RADIATION DOSE; STATISTICAL ANALYSIS; TASTE AVERSION; WEIGHT REDUCTION;

ADULT; CHLORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOUTH MUCOSA; MUCOSITIS; NASOPHARYNGEAL NEOPLASMS; OXIDES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS;

EID: 34548668409     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis - complicating the treatment of cancer. Neoplasia 2004; 6: 423-31.
2. Jansma J, Vissink A, Spijkervet FK, Roodenburg JL, Panders AK, Vermey A, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 1992; 70: 2171-80.
3. Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, et al. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313. Cancer 1992; 69: 2744-8.
4. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-11.
5. Kostler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 2001; 51: 290-315.
6. Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep 2003; 10: 197-206.
7. Schempp H, Reim M, Dornisch K, Elstner EF. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10. Arzneimittelforschung 2001; 51: 554-62.
8. McGrath MS, Benike C, Kuehne FW, Engleman E. Effect of WF10 (TCDO) on antigen presentation. Transplant Proc 1998; 30: 4200-4.
9. McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs 2002; 3: 365-73.
10. Hinz J, Hautzinger H, Stahl KW. Rationale for and results from a randomised, double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Lancet 1986; 1: 825-8.
11. Breiter N, Sassy T, Trott KR. Tetrachlorodecaoxygen anion complex treatment after localized X irradiation of the rat colon. Br J Radiol 1989; 62: 381-3.
12. Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, et al. Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial. Radiother Oncol 2004; 73: 179-85.
13. Veerasarn V, Boonnuch W, Kakanaporn C. A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis. Gynecol Oncol 2006; 100: 179-84.
14. Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer SC. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol 2004; 229: 149-58.
15. Park E, Jia J, Quinn MR, Schuller-Levis G. Taurine chloramine inhibits lymphocyte proliferation and decreases cytokine production in activated human leukocytes. Clin Immunol 2002; 102: 179-84.
16. Barua M, Liu Y, Quinn MR. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: decreased NF-kappaB activation and IkappaB kinase activity. J Immunol 2001; 167: 2275-81.
17. Marcinkiewicz J, Grabowska A, Bereta J, Stelmaszynska T. Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J Leukoc Biol 1995; 58: 667-74.
18. Chorazy M, Kontny E, Marcinkiewicz J, Maslinski W. Taurine chloramine modulates cytokine production by human peripheral blood mononuclear cells. Amino Acids 2002; 23: 407-13.
19. Schuller-Levis GB, Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res 2004; 29: 117-26.
20. Marcinkiewicz J. Prostanoids and MPO-halide system products as a link between innate and adaptive immunity. Immunol Lett 2003; 89: 187-91.
21. Kontny E, Szczepanska K, Kowalczewski J, Kurowska M, Janicka I, Marcinkiewicz J, et al. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 2000; 43: 2169-77.